IN2014DN08158A - - Google Patents

Info

Publication number
IN2014DN08158A
IN2014DN08158A IN8158DEN2014A IN2014DN08158A IN 2014DN08158 A IN2014DN08158 A IN 2014DN08158A IN 8158DEN2014 A IN8158DEN2014 A IN 8158DEN2014A IN 2014DN08158 A IN2014DN08158 A IN 2014DN08158A
Authority
IN
India
Prior art keywords
disclosed
methods
function
specific inhibitor
smad7 expression
Prior art date
Application number
Other languages
English (en)
Inventor
Giovanni Monteleone
Peter Buchwald
Luca Inverardi
Antonello Pileggi
Camillo Ricordi
Alice Tomei
Original Assignee
Nogra Pharma Ltd
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd, Univ Miami filed Critical Nogra Pharma Ltd
Publication of IN2014DN08158A publication Critical patent/IN2014DN08158A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN8158DEN2014 2012-04-18 2013-04-18 IN2014DN08158A (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
PCT/US2013/037150 WO2013158868A1 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Publications (1)

Publication Number Publication Date
IN2014DN08158A true IN2014DN08158A (me) 2015-05-01

Family

ID=48326412

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8158DEN2014 IN2014DN08158A (me) 2012-04-18 2013-04-18

Country Status (15)

Country Link
US (3) US10081809B2 (me)
EP (1) EP2839004B1 (me)
JP (2) JP6348484B2 (me)
KR (1) KR20150003824A (me)
CN (2) CN107252492A (me)
AU (1) AU2013249191B2 (me)
CA (1) CA2870547A1 (me)
DK (1) DK2839004T3 (me)
ES (1) ES2732252T3 (me)
HK (1) HK1207117A1 (me)
IN (1) IN2014DN08158A (me)
MX (1) MX370149B (me)
NZ (1) NZ630914A (me)
RU (1) RU2667960C2 (me)
WO (1) WO2013158868A1 (me)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
KR102099990B1 (ko) 2011-09-15 2020-04-13 노그라 파마 리미티드 항-smad7 요법의 반응성을 모니터링하는 방법
AU2013249191B2 (en) 2012-04-18 2019-01-03 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
EP2940115B1 (en) * 2014-04-30 2018-10-17 The Procter and Gamble Company Cleaning composition
MA39963A (fr) 2014-05-09 2017-03-15 Nogra Pharma Ltd Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
ES2718380T3 (es) * 2015-10-29 2019-07-01 Procter & Gamble Composición detergente líquida
WO2017147276A1 (en) 2016-02-23 2017-08-31 Celgene Corporation Methods of treating intestinal fibrosis using smad7 inhibition
US11584935B2 (en) * 2018-05-08 2023-02-21 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
DK1456380T3 (da) * 2001-11-02 2012-07-30 Giuliani Int Ltd SMAD7-inhibitorer til behandling af CNS-sygdomme
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7786290B2 (en) 2003-06-13 2010-08-31 Alnylam Pharmaceuticals, Inc. Double-stranded ribonucleic acid with increased effectiveness in an organism
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
GB0326778D0 (en) 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
KR101409241B1 (ko) 2004-09-28 2014-06-24 쿠아크 파마수티칼스 인코퍼레이티드 탈모증, 급성신부전증 및 다른 질환의 치료를 위한 올리고리보뉴클레오티드 및 그것의 사용방법
RU2434942C2 (ru) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний
WO2007039151A1 (en) 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
PL2982753T3 (pl) 2008-04-18 2019-03-29 Baxter International Inc. Kompozycja na bazie mikrosfer do zapobiegania i/lub cofania nowego przypadku cukrzycy autoimmunologicznej
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
KR102099990B1 (ko) 2011-09-15 2020-04-13 노그라 파마 리미티드 항-smad7 요법의 반응성을 모니터링하는 방법
AU2013249191B2 (en) 2012-04-18 2019-01-03 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
JP6502863B2 (ja) 2013-03-15 2019-04-17 ノグラ ファーマ リミテッド 結腸直腸癌を処置する方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
MA39963A (fr) 2014-05-09 2017-03-15 Nogra Pharma Ltd Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
CA3000569A1 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
US20210207143A1 (en) 2016-02-24 2021-07-08 Nogra Pharma Limited Methods of Treating Celiac Disease Using SMAD7 Inhibition
WO2018122376A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
HK1207117A1 (en) 2016-01-22
JP6348484B2 (ja) 2018-06-27
US20150315573A1 (en) 2015-11-05
MX2014012650A (es) 2015-04-08
AU2013249191A1 (en) 2014-10-09
NZ630914A (en) 2017-01-27
EP2839004A1 (en) 2015-02-25
ES2732252T3 (es) 2019-11-21
CN104487574A (zh) 2015-04-01
CN104487574B (zh) 2017-07-07
AU2013249191B2 (en) 2019-01-03
JP2015514778A (ja) 2015-05-21
JP2018131468A (ja) 2018-08-23
RU2667960C2 (ru) 2018-09-25
US20200239884A1 (en) 2020-07-30
EP2839004B1 (en) 2019-06-12
DK2839004T3 (da) 2019-07-01
US20190136237A1 (en) 2019-05-09
KR20150003824A (ko) 2015-01-09
MX370149B (es) 2019-12-03
WO2013158868A1 (en) 2013-10-24
US10443056B2 (en) 2019-10-15
CA2870547A1 (en) 2013-10-24
CN107252492A (zh) 2017-10-17
US10081809B2 (en) 2018-09-25
RU2014146170A (ru) 2016-06-10

Similar Documents

Publication Publication Date Title
IN2014DN08158A (me)
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
MX2015013154A (es) Uso de higado desceluralizado por perfusion para receluralizacion de celulas de islote.
UA118328C2 (uk) Спосіб інтегрування екзогенних послідовностей у геном рослинної клітини
PH12014501429A1 (en) Differentiation of human embryonic stem cells into single hormonal insulin positive cells
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX355728B (es) Inhibidores de cinasas.
PH12014502588A1 (en) Catechol o-methyltransferase activity inhibiting compounds
PH12014500995A1 (en) Pak inhibitors for the treatment of cell proliferative disorders
MX343738B (es) Composiciones bioactivas de chromobacterium y metabolitos.
MX371176B (es) Cartuchos de fibra hueca y componentes y métodos para su construcción.
IN2014DN11201A (me)
PH12014502513A1 (en) Nampt inhibitors
SG11201505965TA (en) Culture method for stable undifferentiated proliferation of pluripotent stem cells
IL262554A (en) Methods for Purifying Progenitor Pancreatic Cells Derived from Multipotential Stem Cells and Methods for Growing Them
MX2021000332A (es) Metodos para tratar rechazo mediado por anticuerpos en pacientes de trasplante de organos con inhibidor de c1-esterasa.
MX348311B (es) Inhibidores nampt.
HK1218430A1 (zh) 通過將幹細胞移植到膽管壁來治療胰腺和肝臟病症的方法
MX337486B (es) Fibras de degradacion controlada.
MX2015003701A (es) Composiciones para tratamiento.
EP2616540A4 (en) METHOD OF EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS
MX2010007945A (es) Preparacion y transplante de celulas de isletas pancreaticas.
MX2015007608A (es) Metodos y composiciones para inhibir cnksr1.
IN2014CN02585A (me)
UA64201U (ru) Способ лечения дегенеративно-дистрофического поражения сухожилия